Similar articles

• Chemotherapy in unresectable head and neck cancer.

  Bölke E, Peiper M, Gripp S. Bölke E, et al. N Engl J Med. 2008 Mar 6;358(10):1075; author reply 1075. doi: 10.1056/NEJMc073272. N Engl J Med. 2008. PMID: 18322292 No abstract available.
• Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment.

  Haddad R, Tishler RB, Norris CM, Mahadevan A, Busse P, Wirth L, Goguen LA, Sullivan CA, Costello R, Case MA, Posner MR. Haddad R, et al. Oncologist. 2003;8(1):35-44. doi: 10.1634/theoncologist.8-1-35. Oncologist. 2003. PMID: 12604730 Review.
• Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.

  Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI; TAX 324 Study Group. Posner MR, et al. N Engl J Med. 2007 Oct 25;357(17):1705-15. doi: 10.1056/NEJMoa070956. N Engl J Med. 2007. PMID: 17960013 Clinical Trial.
• Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

  Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL; EORTC 24971/TAX 323 Study Group. Vermorken JB, et al. N Engl J Med. 2007 Oct 25;357(17):1695-704. doi: 10.1056/NEJMoa071028. N Engl J Med. 2007. PMID: 17960012 Clinical Trial.
• [The role of taxanes for head and neck cancer].

  Kohno N. Kohno N. Gan To Kagaku Ryoho. 2005 Dec;32(13):2035-9. Gan To Kagaku Ryoho. 2005. PMID: 16352925 Review. Japanese.